Franchise opportunities compared

    Allegra Network LLC vs Galt Pharmaceuticals

    Reviewed figures from each brand's Franchise Disclosure Document (FDD), side by side. Each figure carries its FDD year and page. This is not a ranking or recommendation, and the two FDDs may cover different years and location groups.

    Initial investment · Item 7

    Allegra Network LLC

    $80,642 – $140,467

    2026 FDD · Item 7

    Galt Pharmaceuticals

    $122,350 – $348,700

    2026 FDD · Item 7 · PDF p. 21

    Initial franchise fee · Item 5

    Allegra Network LLC

    $45,000

    2026 FDD · Item 5 · PDF p. 16

    Galt Pharmaceuticals

    $100,000

    2026 FDD · Item 5 · PDF p. 13

    Royalty · Item 6

    Allegra Network LLC

    6%

    2026 FDD · Item 6 · PDF p. 18

    Galt Pharmaceuticals

    Not available

    Before you compare

    • Both sets of figures come from 2026 FDDs.
    • Allegra Network LLC discloses more than one business format, so the investment range spans formats; the full report breaks them out.
    • Item 19 figures cover the location groups each FDD names (Allegra Network LLC: 4, Galt Pharmaceuticals: 4). Different groups are not directly comparable.

    Financial commitment

    Estimated initial investment (Item 7)

    Allegra Network LLC

    $80,642 – $140,467
    2026 FDD · Item 7

    Galt Pharmaceuticals

    $122,350 – $348,700
    Total initial investment: $122,350 to $348,700
    2026 FDD · Item 7 · PDF p. 21
    Standard initial franchise fee (Item 5)

    Allegra Network LLC

    $45,000
    2026 FDD · Item 5 · PDF p. 16

    Galt Pharmaceuticals

    $100,000
    The FDD also lists a past-fiscal-year initial franchise fee range of $125,000 to $300,000.
    2026 FDD · Item 5 · PDF p. 13
    Royalty (Item 6)

    Allegra Network LLC

    6%
    Royalty sliding scale
    2026 FDD · Item 6 · PDF p. 18

    Galt Pharmaceuticals

    Not available
    No reviewed royalty record
    Brand / advertising fund (Item 6)

    Allegra Network LLC

    1%
    Marketing Fund: Allegra and American Speedy Printing Centers — 1%
    2026 FDD · Item 6 · PDF p. 18

    Galt Pharmaceuticals

    $1,000
    Marketing Fee maximum: $1,000 per month per territory
    2026 FDD · Item 6 · PDF p. 15

    System scale & health

    Total outlets (Item 20)

    Allegra Network LLC

    167
    Outlets at end of 2025
    2025 FDD · Item 20 · PDF p. 60

    Galt Pharmaceuticals

    63
    Outlets at end of 2025
    2026 FDD · Item 20 · PDF p. 48
    Net outlet change (Item 20)

    Allegra Network LLC

    −77
    Calculated: 244 at end of 2022 → 167 at end of 2025

    Galt Pharmaceuticals

    −3
    Calculated: 66 at end of 2023 → 63 at end of 2025
    Outlet exits (Item 20)

    Allegra Network LLC

    Not available
    No complete exit records for a year

    Galt Pharmaceuticals

    0
    Closures, terminations & non-renewals in 2025 · Calculated turnover 0.0% of outlets at start of year
    2026 FDD · Item 20 · PDF p. 48
    Franchising since (Item 1)

    Allegra Network LLC

    Not available
    Not in reviewed records

    Galt Pharmaceuticals

    Not available
    Not in reviewed records
    Franchisor founded (Item 1)

    Allegra Network LLC

    Not available
    Not in reviewed records

    Galt Pharmaceuticals

    Not available
    Not in reviewed records

    Financial performance (Item 19), by location group

    Allegra Network LLC
    Locations counted not stated in the reviewed record — Top 50% of the eligible franchised Allegra Centers operating at least one full…
    $1,719,843
    other Top 50% average annual Royalty-Based Sales: $1,719,843.
    2026 FDD · Item 19 · PDF p. 57
    Locations counted not stated in the reviewed record — Allegra U.S. Participating Centers in the Operating Ratio Study for fiscal year…
    $1,523,781
    other Operating Ratio Study average Gross Revenue: $1,523,781.
    2026 FDD · Item 19 · PDF p. 58
    Locations counted not stated in the reviewed record — All franchised Allegra Centers in the U.S. operating at least one full calendar…
    $1,080,898
    other All franchised Allegra Centers average annual Royalty-Based Sales: $1,080,898.
    2026 FDD · Item 19 · PDF p. 57
    +1 more groups in the full report
    Galt Pharmaceuticals
    Locations counted not stated in the reviewed record — Bottom third of 24 Operational Franchise Outlets; reporting period 2025.
    $12,142
    other Bottom third
    2026 FDD · Item 19 · PDF p. 46
    Locations counted not stated in the reviewed record — Middle third of 24 Operational Franchise Outlets; reporting period 2025.
    $66,763
    other Middle third
    2026 FDD · Item 19 · PDF p. 46
    Locations counted not stated in the reviewed record — Top third of 24 Operational Franchise Outlets; reporting period 2025.
    $813,752
    other Top third
    2026 FDD · Item 19 · PDF p. 46
    +1 more groups in the full report

    Item 19 groups are shown separately and never combined. Revenue or sales figures are not profit. Net outlet change and turnover are Franopolis calculations from the disclosed counts; turnover is a count-based rate, not a measure of owner earnings.

    Allegra Network LLC vs Galt Pharmaceuticals: common questions

    Which costs less to open, Allegra Network LLC or Galt Pharmaceuticals?
    Allegra Network LLC: $80,642 – $140,467 (2026 FDD · Item 7); Galt Pharmaceuticals: $122,350 – $348,700 (2026 FDD · Item 7 · PDF p. 21). These are each franchisor's Item 7 estimated initial investment. The low end of the disclosed estimate is lower for Allegra Network LLC. At least one range spans several business formats. Estimates are not quotes, and the FDD years may differ.
    Which has more locations, Allegra Network LLC or Galt Pharmaceuticals?
    Allegra Network LLC: 167 (2025 FDD · Item 20 · PDF p. 60); Galt Pharmaceuticals: 63 (2026 FDD · Item 20 · PDF p. 48). Total outlets from Item 20. Outlet counts do not indicate territory availability or franchisee results.
    Do Allegra Network LLC and Galt Pharmaceuticals disclose financial performance (Item 19)?
    Allegra Network LLC has reviewed Item 19 figures for 4 location groups; Galt Pharmaceuticals has reviewed Item 19 figures for 4 location groups. Different location groups are not directly comparable, and revenue is not profit.

    Answers restate the reviewed figures above. Not a ranking or recommendation.

    How Franopolis reviews FDD figures

    Keep researching